X4 Pharmaceuticals Inc Total Assets
X4 Pharmaceuticals Inc total assets. Based on the latest financial reports, X4 Pharmaceuticals Inc (XFOR) holds total assets worth $253.06 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see X4 Pharmaceuticals Inc (XFOR) total market value for the company's overall valuation and market capitalisation.
Total Assets of X4 Pharmaceuticals Inc (2015–2025)
Total assets of X4 Pharmaceuticals Inc from 2015 to 2025. This chart illustrates how X4 Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See XFOR live share price for real-time trading data and today's change.
X4 Pharmaceuticals Inc - Asset Composition Analysis
X4 Pharmaceuticals Inc Total Assets Breakdown (December 2025)
X4 Pharmaceuticals Inc total assets breakdown as of December 2025. X4 Pharmaceuticals Inc's total assets of $253.06 Million consist of 90.1% current assets and 9.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 74.7% |
| Accounts Receivable | $573.00K | 0.2% |
| Inventory | $4.48 Million | 1.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.25 Million | 3.2% |
| Goodwill | $17.35 Million | 6.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how X4 Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore X4 Pharmaceuticals Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: X4 Pharmaceuticals Inc's current assets represent 90.1% of total assets in 2025, an increase from 88.2% in 2015.
- Cash Position: Cash and equivalents constituted 74.7% of total assets in 2025, up from 71.1% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 6.0% of total assets.
X4 Pharmaceuticals Inc Competitors by Total Assets
Key competitors of X4 Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
X4 Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 11.30 | 3.19 | 6.10 |
| Quick Ratio | 11.02 | 3.05 | 6.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $199.49 Million | $50.05 Million | $67.47 Million |
X4 Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between X4 Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.95 |
| Asset Growth Rate (YoY) | 98.3% |
| Total Assets | $290.46 Million |
| Market Capitalization | $276.62 Million USD |
Valuation Analysis
Near Book Valuation: The market values X4 Pharmaceuticals Inc's assets close to their book value (0.95x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: X4 Pharmaceuticals Inc's assets grew by 98.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for X4 Pharmaceuticals Inc (2015–2025)
The table below shows the annual total assets of X4 Pharmaceuticals Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $290.46 Million | +98.34% |
| 2024-12-31 | $146.45 Million | -0.55% |
| 2023-12-31 | $147.26 Million | -5.35% |
| 2022-12-31 | $155.59 Million | +32.78% |
| 2021-12-31 | $117.18 Million | -4.63% |
| 2020-12-31 | $122.87 Million | -23.54% |
| 2019-12-31 | $160.70 Million | +346.33% |
| 2018-12-31 | $36.00 Million | -55.69% |
| 2017-12-31 | $81.25 Million | +968.57% |
| 2016-12-31 | $7.60 Million | -20.04% |
| 2015-12-31 | $9.51 Million | -- |
About X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections… Read more